LEXINGTON, Mass. and HEIDELBERG, Germany, May 27 febittoday announced the receipt of US patent #7320862 on its microfluidicmicroarray-based method for extraction of DNA and RNA.
This method forms the basis of a novel technology that enables theexpanded use of next-generation sequencers in genomic research. Furtherinvestigation of the human genome by resequencing will particularly benefitfrom the new method: febit uses its microfluidic biochip system forsequence-based selective isolation of nucleic acids from genomic samples. Thisnew approach to high-throughput sequencing essentially relies on high-densitymicroarray biochips with flexible design, a technology established by febitseveral years ago. The newly patented method is known as hybselect, targetedsequencing or sequence capture. Using this innovative technique, researchersare able to isolate genes or genomic regions of interest from a complex DNAsample prior to sequencing.
febit microfluidic biochip systems have been successfully used for severalyears in DNA analysis and synthesis. The latest patent was now granted in theUS, patents in Europe and other foreign countries will soon follow.
febit currently holds more than 20 patents and patent applications. Inaddition to bioanalytics, the company's intellectual property portfoliopredominantly covers the production of synthetic genes on biochips, an areawhere febit holds several key patents. Using a focussed application strategy,febit has been able to secure intellectual property rights on importantproduct components, processes and evolving technologies.
febit enables scientists to read, write and understand the code of life:DNA. With its unique Geniom technology and services, febit is the only companythat puts the control of simplified genomic research in the hand of the user.The seamless integration of DNA synthesis and analysis and the superiorsupport in experiment design and bioinformatics helps to understand data andturn it into results. febit's team of experienced scientists is dedicated tosupport customers to solve the challenge of understanding biologicalprocesses. Geniom is a technological and service platform successfullyimplemented in basic and applied research by renowned institutions andcompanies. Geniom exploits cutting-edge microarray technology for analysis andsynthesis of genes and genomes, providing superior time- and cost-efficiencycombined with an unsurpassed spectrum of applications.www.febit.com Contact: febit holding gmbh Russo Partners, LLC Eva Sterzel David Schull or Wendy Lau Public Relations Manager +1-212-845-4271 +49 (6221) 6510-300 [email protected] [email protected] [email protected]